LETICIA PILAR: Open Payments
NPI 1437705852 · COPPELL, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,358 in 115 payments from 27 companies in 2025. Trend: 2023 $739 · 2024 $2,151 · 2025 $2,358
Food & beverage: $2,259Education: $99
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $266 |
| Novo Nordisk Inc | 12 | $237 |
| AstraZeneca Pharmaceuticals LP | 9 | $227 |
| Astellas Pharma US Inc | 6 | $211 |
| ABBVIE INC. | 13 | $209 |
| Lilly USA, LLC | 11 | $175 |
| PFIZER INC. | 10 | $141 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $107 |
| Amgen Inc. | 5 | $83 |
| Axsome Therapeutics, Inc. | 3 | $71 |
Products named: REXULTI, JARDIANCE, VRAYLAR, Veozah, FARXIGA, Ozempic, MOUNJARO, Wegovy.
Industry payments across TX — which companies pay providers there.
